Pharmacokinetic Profile of Semaglutide in Canines
Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
February 05, 2025 16:05 ET | Rani Therapeutics, LLC
- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...
Amid Novo Nordisk’s
Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization
February 05, 2025 09:33 ET | Spherix Global Insights
EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis...
LOGO - Color (1).jpg
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
February 04, 2025 08:00 ET | PMGC Holdings Inc.
Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio
LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
January 30, 2025 08:00 ET | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Th
LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
January 24, 2025 08:00 ET | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
Digbi New Logo.png
Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
January 17, 2025 05:21 ET | Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
tiziana-logo.png
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
January 10, 2025 08:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Americans Weigh In:
Americans Weigh In: International Food Information Council Releases New Research Examining Perceptions Around Obesity & Weight Loss Medications
January 08, 2025 11:23 ET | International Food Information Council Foundation
Washington, DC, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The International Food Information Council (IFIC) has published a new survey examining Americans’ attitudes and perceptions toward obesity...
Semaglutides Market Report 2024
Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, AbbVie, and Sanofi
January 06, 2025 04:12 ET | Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering.This Semaglutides market report covers market...
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
December 09, 2024 08:00 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl